The scientific world has seen a dramatic increase in meetings and workshops dedicated to immunotherapy. Ours, the Immunotherapy Workshop: Incorporating Radiation Oncology into Immunotherapy, included. With all these meetings, how is ours any different? Why should immunologists and radiation oncologists attend?
1. Sessions will focus on combining therapies
Data are emerging demonstrating that the combination of immunotherapy and radiation therapy may improve efficacy, may lead to an increase in percentage of patients who respond to immunotherapy and may improve patient outcomes. Questions about dosing, sequencing of treatment and how these therapies work, however, are still unanswered. This workshop will address these and other outstanding questions.
2. Leaders in radiation oncology and immunology are the speakers
Participants will hear from leaders in both fields, including keynote speakers Silvia Formenti, MD, FASTRO, and Ralph Weichselbaum, MD. Panel speakers include Sandra Demaria, MD, Phuoc Tran, MD, PhD, Chandan Guha, MD, PhD, Yvonne Mowery, MD, PhD, Lisa Butterfield, PhD, Timothy Chan, MD, PhD, Sridhar Nimmagadda, PhD, Max Diehn, MD, PhD, Marka Crittenden, MD, PhD, James Welsh, MD, and Michael Lim, MD.Junior faculty and other trainees have the potential to speak, as three additional short talks will be selected from the submitted abstracts to be included in each of the panel sessions.
3. Intimate meeting allows for increased interactions
Our meeting is 1 1/2 days and held on the National Institutes of Health campus. Poster sessions mid-day on day one provide optimal time to network, to see the latest cutting-edge data and to participate in discussions about the topics. Our intimate setting provides ample opportunity and time for engagement.
4. Breakout sessions will engage participants along with speakers
The breakout sessions on day two are designed to continue the discussions from the panel sessions on day one and allow all participants to join the dialogue. This format allows for robust engagement of all meeting participants and for new ideas and collaborations to emerge.
5. Goal is to produce manuscripts and grants that incorporate radiation oncology into immunotherapy
Our goal is to hold a robust conversation about radiation and immunotherapy. In the end, participants will write and publish several manuscripts about each topic.
April 21, 2017 is the deadline for abstract submission. Early-bird registration closes on April 19.